[go: up one dir, main page]

PL2076506T3 - Heterocyklicznie podstawione piperydyny jako ligandy ORL-1 - Google Patents

Heterocyklicznie podstawione piperydyny jako ligandy ORL-1

Info

Publication number
PL2076506T3
PL2076506T3 PL08727696T PL08727696T PL2076506T3 PL 2076506 T3 PL2076506 T3 PL 2076506T3 PL 08727696 T PL08727696 T PL 08727696T PL 08727696 T PL08727696 T PL 08727696T PL 2076506 T3 PL2076506 T3 PL 2076506T3
Authority
PL
Poland
Prior art keywords
heterocyclic
orl
ligands
substituted piperidines
substituted piperidine
Prior art date
Application number
PL08727696T
Other languages
English (en)
Inventor
Yoshiyasu Baba
Kevin C Brown
R Richard Goehring
Naoki Tsuno
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Publication of PL2076506T3 publication Critical patent/PL2076506T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL08727696T 2007-01-16 2008-01-15 Heterocyklicznie podstawione piperydyny jako ligandy ORL-1 PL2076506T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88095507P 2007-01-16 2007-01-16
US93003507P 2007-05-11 2007-05-11
PCT/US2008/051096 WO2008089201A2 (en) 2007-01-16 2008-01-15 Heterocyclic-substituted piperidine as orl-1 ligands
EP08727696A EP2076506B1 (en) 2007-01-16 2008-01-15 Heterocyclic-substituted piperidines as orl-1 ligands

Publications (1)

Publication Number Publication Date
PL2076506T3 true PL2076506T3 (pl) 2011-03-31

Family

ID=39434287

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08727696T PL2076506T3 (pl) 2007-01-16 2008-01-15 Heterocyklicznie podstawione piperydyny jako ligandy ORL-1

Country Status (23)

Country Link
US (2) US8110602B2 (pl)
EP (3) EP2076506B1 (pl)
JP (2) JP5462633B2 (pl)
KR (2) KR101370434B1 (pl)
CN (1) CN101595100B (pl)
AT (1) ATE482206T1 (pl)
AU (2) AU2008206317B2 (pl)
CA (1) CA2675419C (pl)
CY (1) CY1111085T1 (pl)
DE (1) DE602008002690D1 (pl)
DK (1) DK2076506T3 (pl)
ES (1) ES2353448T3 (pl)
HK (1) HK1152296A1 (pl)
HR (1) HRP20100691T1 (pl)
IL (1) IL199741A0 (pl)
MX (1) MX2009007644A (pl)
NZ (2) NZ578078A (pl)
PL (1) PL2076506T3 (pl)
PT (1) PT2076506E (pl)
RS (1) RS51474B (pl)
SI (1) SI2076506T1 (pl)
WO (1) WO2008089201A2 (pl)
ZA (1) ZA200903742B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2076506T3 (da) 2007-01-16 2011-01-10 Purdue Pharma Lp Heterocyklisk substituerede piperidiner som ORL-1-ligander
MX379353B (es) 2007-08-31 2025-03-10 Purdue Pharmal P Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
DK2324013T6 (en) 2008-07-21 2014-12-15 Purdue Pharma Lp Substituted bridged piperidine compounds of quinoxalintype and uses thereof
WO2010090198A1 (ja) * 2009-02-03 2010-08-12 田辺三菱製薬株式会社 １－（４－ピペリジニル）ベンゾイミダゾロン誘導体の製造方法
KR20120069710A (ko) 2009-09-08 2012-06-28 교린 세이야꾸 가부시키 가이샤 ４?(５?메틸피리딘?２?일아미노)피페리딘?１?카복실산 유도체의 제조방법
EP2631229B1 (en) * 2010-07-29 2014-12-03 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
TWI793877B (zh) * 2020-11-26 2023-02-21 南韓商Ｌｇ化學股份有限公司 作為甘油二酯激酶抑制劑的雜環化合物及其用途
KR20230164601A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
KR20230164602A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
EP0556393B1 (en) 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9314977D0 (en) 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
US5739129A (en) 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CZ189197A3 (cs) * 1994-12-23 1998-01-14 Dr. Karl Thomae Gmbh Piperazinové deriváty, způsob výroby a farmaceutický prostředek s jejich obsahem
JP3845876B2 (ja) 1995-04-20 2006-11-15 アステラス製薬株式会社 ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
AU732329B2 (en) * 1997-05-30 2001-04-12 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
US6030130A (en) * 1997-07-07 2000-02-29 George Paddock Ii, Inc. Body mounted camera support system
DE69901934T2 (de) * 1998-01-19 2002-11-07 Pfizer Inc., New York 4-(2-keto-1-benzimidazolinyl)piperidin derivate als orl1-rezeptor agoniste
AU3053999A (en) * 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) * 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
AU6124599A (en) 1998-10-20 2000-05-08 Takeda Chemical Industries Ltd. 1,5-benzodiazepine compounds, process for producing the same, and medicine
EP1230220A1 (en) 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
US7456198B2 (en) * 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002080895A2 (en) 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
EP1997818A3 (en) * 2001-04-18 2009-04-08 Euro-Celtique S.A. Quinolinone derivatives and their use to treat pain
SI1385518T1 (sl) * 2001-04-18 2009-02-28 Euro Celtique Sa Benzimidazolonske spojine
SI1385515T1 (sl) 2001-04-18 2008-12-31 Euro Celtique Sa Spiropirazolne spojine
DE60232752D1 (de) * 2001-04-18 2009-08-06 Euro Celtique Sa 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20080214827A1 (en) * 2004-02-03 2008-09-04 Euro-Celtique S.A. Synthesis of Cyanoimino-Benzoimidazoles
US7459556B2 (en) * 2004-09-15 2008-12-02 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols
DK2076506T3 (da) 2007-01-16 2011-01-10 Purdue Pharma Lp Heterocyklisk substituerede piperidiner som ORL-1-ligander

Also Published As

Publication number Publication date
CN101595100A (zh) 2009-12-02
AU2008206317A1 (en) 2008-07-24
US8110602B2 (en) 2012-02-07
EP2076506B1 (en) 2010-09-22
EP2397477B1 (en) 2014-03-05
CA2675419A1 (en) 2008-07-24
EP2280008B1 (en) 2013-05-29
EP2397477A1 (en) 2011-12-21
EP2076506A2 (en) 2009-07-08
ATE482206T1 (de) 2010-10-15
KR20090101314A (ko) 2009-09-24
KR101227072B1 (ko) 2013-01-29
JP2010516687A (ja) 2010-05-20
AU2011200692A1 (en) 2011-03-10
DK2076506T3 (da) 2011-01-10
KR20120051759A (ko) 2012-05-22
AU2008206317B2 (en) 2012-02-02
US8637502B2 (en) 2014-01-28
JP5462633B2 (ja) 2014-04-02
WO2008089201A2 (en) 2008-07-24
US20100022519A1 (en) 2010-01-28
MX2009007644A (es) 2009-07-27
CN101595100B (zh) 2014-06-11
ES2353448T3 (es) 2011-03-02
DE602008002690D1 (de) 2010-11-04
KR101370434B1 (ko) 2014-03-06
IL199741A0 (en) 2010-04-15
PT2076506E (pt) 2010-12-10
EP2280008A2 (en) 2011-02-02
SI2076506T1 (sl) 2011-01-31
NZ601683A (en) 2012-11-30
HK1152296A1 (en) 2012-02-24
AU2011200692B2 (en) 2012-02-09
NZ578078A (en) 2011-11-25
JP2014040467A (ja) 2014-03-06
CA2675419C (en) 2013-11-12
CY1111085T1 (el) 2015-06-11
RS51474B (en) 2011-04-30
US20120108575A1 (en) 2012-05-03
WO2008089201A3 (en) 2008-12-18
ZA200903742B (en) 2010-02-24
HRP20100691T1 (hr) 2011-01-31
EP2280008A3 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
HK1152296A1 (en) Heterocyclic-substituted piperidines as orl-1 ligands
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MY148657A (en) Trpv1 antagonists and uses thereof
HK1186127A1 (zh) 通過給予神經生長因子拮抗劑及其組合物來治療骨關節炎疼痛的方法
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EP2282737A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIODONTAL PATHOLOGY COMPRISING CLONIDINE, SULINDAC AND / OR FLUOCINOLONE
TW200744586A (en) Therapeutic compounds
WO2009147205A3 (en) Synergistic fungicidal mixtures
WO2009000843A3 (fr) Traitement de l&#39;insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l&#39;aldostérone
WO2008112647A3 (en) Nitroxide radical as a treatment for neurodegeneration
WO2014102594A3 (en) Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014020405A8 (en) Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
IL196561A0 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
WO2010097576A8 (en) 1, 4-disubstituted piperidines as vasopressin receptor via antagonists
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
UA92444C2 (uk) Фунгіцидна суміш тритиконазолу і дифеноконазолу, композиція на її основі та спосіб боротьби зі шкідливими фітопатогенними грибами
MX2011003306A (es) Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
UA101954C2 (ru) Замещенные ароматические гетероциклические соединения как фунгициды
WO2006138589A3 (en) Opioid receptor ligands
UA97540C2 (ru) Замещенные хиноксалином пиперидиновые соединения и их применение
TNSN05114A1 (en) 4-tetrazolyl -4 phenylpiperidine derivatives for treating pain